A phase I study to assess the safety, tolerability, pharmacokinetic profile and pharmacodynamic effect of single and multiple doses of VAK694 in healthy and atopic subjects

Trial Profile

A phase I study to assess the safety, tolerability, pharmacokinetic profile and pharmacodynamic effect of single and multiple doses of VAK694 in healthy and atopic subjects

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Mar 2008

At a glance

  • Drugs VAK 694 (Primary)
  • Indications Allergic rhinitis
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Novartis
  • Most Recent Events

    • 26 Mar 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top